The Use of Opioids in the Last Week of Life in an Acute Palliative Care Unit

Abstract

The aim of this survey was to assess the opioid use in the last week of life of cancer patients admitted at an acute palliative care unit. From a consecutive sample of patients surveyed for a period of one year, patients who died in the unit were selected. Type of opioid, route of administration, and doses were recorded one week before death (or at admission time if the interval admission-death was less than one week) (-7), and on the day of death (Tend). Seventy-seven patients died in the unit in the period taken into consideration (12.4%). Oral morphine equivalents were 170 mg/day and 262 mg/day at -7 and Tend, respectively. Patients were receiving transdermal drugs or intravenous morphine at Tend, with a trend in the use of intravenous morphine at Tend (p=0.07). Intravenous morphine was more frequently used in sedated patients at Tend (p=0.015).No differences in age, gender, opioid doses, and OEI were found among opioids used. In patients who were sedated doses of opioids were significantly increased (p=0.012). In the last week of life intravenous morphine is the preferred modality to deliver opioids in an acute palliative care unit. Doses increases prevalently observed in sedated patients were performed before starting sedation with the purpose to treat concomitant distressing symptoms, such as dyspnoea.

Keywords

opioids end of life intravenous morphine

Get full access to this article

View all access options for this article.

References

Portenoy RK , Sibirceva U. , Smout R. , et al. Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manage. 2006;32(6):532-540.

Morita T. , Tsunoma J. , Inoue S. , Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage. 2001;21(4):282-289.

Thorns A. , Sykes N. Opioid use in the last week of life and implications for end-of-life decision-making . Lancet. 2000;356(9227): 398-399.

Coyle N. , Adelhardt J. , Foley KM , Portenoy RK Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage. 1990;5(2):83-93.

Fainsinger RL , Waller A. , Bercovich M. , et al. A muticentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med. 2000;14(4):257-265.

Mercadante S. , Casuccio A. , Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage. 2000;20(2):104-112.

Ellershaw J. , Gambles M. , McGlinchey T.

Benchmarking: a useful tool for informing and improving care of the dying?

Support Care Cancer. 2008;16(7):813-819.

Mercadante S. , Intravaia G. , Villari P. , Ferrera P. , David F. , Casuccio A. Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage. 2009;37(5):771-779.

Mercadante S. , Fulfaro F. , Casuccio A. , Barresi L. Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manage. 1999;18(5):347-352.

10.

Mercadante S. , Ferrera P. , Villari P. , Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol. 2005;23(22):5229-5234.

11.

Sykes N. , Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol. 2003;4(5):312-318.

12.

Schiessl C. , Sittl R. , Griessinger N. , Lutter N. , Schuettler J. Intravenous morphine consumption in outpatients with cancer during their last week of life-an analysis based on patient-controlled analgesia data. Support Care Cancer. 2008;16(8): 917-923.

13.

Bercovitch M. , Adunsky A.

Patterns of high dose morphine use in a home-care hospice service. Should we be afraid of it?

Cancer. 2004;101(6):1473-1437.

14.

Chater S. , Viola R. , Paterson J. Jarvis V. Sedation for intractable distress in the dying-a survey of experts . Palliat Med. 1998; 12(4):255-269.

15.

Good PD , Ravenscroft PJ , Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. Intern Med J. 205;35(9):512-517.

16.

Mercadante S. , Intravaia G. , Villari P. , Ferrera P. , David F. , Casuccio A. Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage. 2009;37(5):771-779.

17.

Kohara H. , Ueoka H. , Takeyama H. , Murakami T. , Morita T. Sedation for terminally ill patients with cancer with uncontrollable physical distress. J Palliat Med. 2005;8(1):20-25.

18.

De Graeff A. , Dean M. Palliative sedation therapy in the last weeks: a literature review and recommendations for standards. J Palliat Med. 2007;10(1):67-85.

19.

Morita T. , Chinone Y. , Ikenaga M. , et al. Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Sypmtom Manage. 2005 ;30(4):320-328.

20.

Miccinesi G. , Rietjens J. , Deliens L. , et al. Continuous deep sedation: physicians’ experiences in six European countries. J Pain Symptom Manage . 2006;31(2):122-129.

21.

Bielsen J. , Norup M. , Deliens L. , et al. Drugs used to alleviate symptoms with life shortening as a possible side effect: end-of-life care in six European countries. J Pain Symptom Manage. 2006;31(2):111-121.

22.

Reuzel RPB , Hasselaar GJ , van der Wilt GJ , Groenewoud JMM , Crul BJP. Inappropriateness of using opioids for end-stage palliative sedation: a Dutch study. Palliat Med. 2008;22(5):641-646.

23.

Mercadante S. , Intravaia G. , Villari P. , et al. Clinical and financial analysis of an acute palliative care unit in an oncological department . Palliat Med. 2008;22(6):760-767.